Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
J&J Veteran To Continue Rebuilding In 2023
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
You may also be interested in...
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.